Global Health Headlines: Drugs, Vaccines, and Policies in Focus
The health sector is seeing delays in drug launches in Europe due to U.S. pricing pressures, liver injury warnings for Amgen's drug, and vaccine disputes. Meanwhile, Novo's heart drug gets the UK's nod and Pfizer wins a court ruling on vaccine deliveries. Obesity drug competition heats up in the U.S.
Drugmakers in Europe are holding back the introduction of new medicines due to price policy changes under pressure from the U.S. administration. This move follows President Donald Trump's efforts to tie U.S. drug costs to prices in other countries, a strategy known as most-favored-nation pricing.
The FDA has issued a warning regarding liver injuries linked to Amgen's drug Tavneos. The agency identified 76 cases of drug-induced liver injury, including seven cases of vanishing bile duct syndrome, prompting healthcare providers to discontinue the drug if liver damage is suspected.
Novo Nordisk's Wegovy has been endorsed by the UK's NICE to lower heart risks, marking it as the first GLP-1 drug approved for this use in obese or overweight adults. Meanwhile, the Belgian court has mandated Poland and Romania to purchase $2.2 billion worth of Pfizer vaccines.
Google News